4TEEN4 Secures €55M to Advance Heart Shock Treatment
The Hennigsdorf company's procizumab targets a critical condition with mortality rates above 50% and no approved treatments available.
Berlin area pharmaceutical company 4TEEN4 has extended its Series C financing round to €55 million to advance clinical trials of procizumab, a potential breakthrough treatment for cardiogenic shock. According to the company's press release, the funding comes from both existing and new investors.
Headquartered in Hennigsdorf near Berlin, 4TEEN4 is developing procizumab as a first-in-class monoclonal antibody targeting circulating dipeptidyl peptidase 3 (cDPP3), a key driver of mortality in shock patients. Cardiogenic shock is a life-threatening condition that occurs when the heart suddenly cannot pump enough blood to meet the body's needs, often following heart attacks or acute heart failure. Despite advances in supportive care, mortality rates exceed 50%, and no approved therapies currently target the underlying causes.
The fresh capital will fund the expansion of the ongoing PROCARD 2a study across Europe and support the planned US expansion. The multicenter Phase 2a trial is evaluating procizumab's safety, tolerability, and effectiveness in cardiogenic shock patients with elevated cDPP3 levels. 4TEEN4 dosed its first patient in July 2025 and expects interim safety and pharmacokinetic results in early 2026.
"This investment enables us to advance our PROCARD 2a study, creating a comprehensive framework for our planned pivotal study for procizumab," said Dr. Andreas Bergmann, CEO of 4TEEN4 Pharmaceuticals, in the company's statement. The proceeds will also strengthen operational readiness ahead of the pivotal trial phase.
CFO Dr. Kilian von Seldeneck emphasized that the funding will help the company reach key clinical milestones while creating long-term value for shareholders. Shock accounts for approximately one in three ICU admissions, representing a significant unmet medical need in critical care.
Thinking about launching a business, setting up premises, or creating partnerships in Berlin?
We invite you to contact us.
Our team is ready to help you with our free consultation services.